Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver DOI
Wenshu Tang, Jingying Zhou, Weiqin Yang

et al.

Cellular and Molecular Immunology, Journal Year: 2022, Volume and Issue: 19(7), P. 834 - 847

Published: May 20, 2022

Language: Английский

Molecular mechanisms in MASLD/MASH-related HCC DOI
Xiaobo Wang, Liang Zhang, Bingning Dong

et al.

Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 13, 2024

Liver cancer is the third leading cause of cancer-related deaths and ranks as sixth most prevalent type globally. NAFLD or metabolic dysfunction-associated steatotic liver disease, its more severe manifestation, NASH steatohepatitis (MASH), pose a significant global health concern, affecting approximately 20%-25% population. The increased prevalence disease MASH parallel to increasing rates obesity-associated diseases, including 2 diabetes, insulin resistance, fatty diseases. can progress MASH-related HCC (MASH-HCC) in about 2% cases each year, influenced by various factors such genetic mutations, carcinogen exposure, immune microenvironment, microbiome. MASH-HCC exhibits distinct molecular characteristics compared other causes affects both men women equally. management early intermediate-stage typically involves surgery locoregional therapies, while advanced treated with systemic anti-angiogenic therapies checkpoint inhibitors. In this comprehensive review, we consolidate previous research findings also providing current insights into intricate processes underlying development. We delve MASH-HCC-associated variations somatic progression models, multiomics analysis, immunological microenvironmental impacts, discuss targeted/combined overcome evasion biomarkers recognize treatment responders. By furthering our comprehension mechanisms MASH-HCC, goal catalyze advancement potent strategies, ultimately enhanced patient outcomes.

Language: Английский

Citations

43

Spatial lipidomics reveals sphingolipid metabolism as anti-fibrotic target in the liver DOI Creative Commons
Aleksandra Gruevska, Jack Leslie,

Eunkyung An

et al.

Metabolism, Journal Year: 2025, Volume and Issue: unknown, P. 156237 - 156237

Published: March 1, 2025

Language: Английский

Citations

2

Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis DOI Creative Commons

Zhongyi Wang,

Adrian Keogh, Annick Waldt

et al.

Scientific Reports, Journal Year: 2021, Volume and Issue: 11(1)

Published: Sept. 29, 2021

Abstract Fibrosis is characterized by the excessive production of collagen and other extracellular matrix (ECM) components represents a leading cause morbidity mortality worldwide. Previous studies nonalcoholic steatohepatitis (NASH) with fibrosis were largely restricted to bulk transcriptome profiles. Thus, our understanding this disease limited an incomplete characterization liver cell types in general hepatic stellate cells (HSCs) particular, given that activated HSCs are major fibrogenic population. To help fill gap, we profiled 17,810 non-parenchymal derived from six healthy human livers. In conjunction public single-cell data fibrotic/cirrhotic livers, these profiles enable identification potential intercellular signaling axes (e.g., ITGAV–LAMC1, TNFRSF11B–VWF NOTCH2–DLL4) master regulators RUNX1 CREB3L1 ) responsible for activation during fibrogenesis. Bulk RNA-seq NASH patient livers rodent models diverse etiologies allowed us evaluate translatability candidate therapeutic targets NASH-related fibrosis. We identified 61 fibrosis-associated genes AEBP1, PRRX1 LARP6 may serve as repertoire translatable drug target candidates. Consistent above regulon results, gene regulatory network analysis regulator many genes. Together, study highlights cell–cell interactions underlie HSC reveals represent prospective hallmark signatures

Language: Английский

Citations

78

Role of bile acids in inflammatory liver diseases DOI Creative Commons
Ioannis Evangelakos, Jöerg Heeren,

Esther Verkade

et al.

Seminars in Immunopathology, Journal Year: 2021, Volume and Issue: 43(4), P. 577 - 590

Published: July 8, 2021

Abstract Bile acids and their signaling pathways are increasingly recognized as potential therapeutic targets for cholestatic metabolic liver diseases. This review summarizes new insights in bile acid physiology, focusing on regulatory roles of the control immune regulation effects pharmacological modulators human disease. Recent mouse studies have highlighted importance interactions between gut microbiome. Interfering with microbiome composition may be beneficial diseases by modulating formation secondary acids, different species functions. receptors such FXR, VDR, TGR5 expressed a variety cells involved innate well adaptive immunity, specific microbial metabolites positively modulate responses host. Identification Cyp2c70 enzyme responsible generation hydrophilic mouse/rat-specific muricholic has allowed murine models human-like composition. These novel will aid to accelerate translational research (patho)physiological .

Language: Английский

Citations

77

Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver DOI
Wenshu Tang, Jingying Zhou, Weiqin Yang

et al.

Cellular and Molecular Immunology, Journal Year: 2022, Volume and Issue: 19(7), P. 834 - 847

Published: May 20, 2022

Language: Английский

Citations

67